Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Inflammopharmacology
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/40617897/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1868266181669945345 |
|---|---|
| author | Manzhulo, Igor Egoraeva, Anastasia Ivashkevich, Darya Manzhulo, Olga Ponomarenko, Arina |
| author_facet | Manzhulo, Igor Egoraeva, Anastasia Ivashkevich, Darya Manzhulo, Olga Ponomarenko, Arina Manzhulo, Igor Egoraeva, Anastasia Ivashkevich, Darya Manzhulo, Olga Ponomarenko, Arina |
| collection | PubMed - marine biology |
| contents | Synaptamide regulates astroglial functional activity after cerebral cortex injury. Manzhulo, Igor Egoraeva, Anastasia Ivashkevich, Darya Manzhulo, Olga Ponomarenko, Arina Animals Astrocytes Mice Cerebral Cortex Male Brain Injuries, Traumatic Ethanolamines Gliosis Neuroprotective Agents Mice, Inbred C57BL Brain-Derived Neurotrophic Factor Modern approaches to the treatment of traumatic brain injury (TBI) focus on alleviating life-threatening conditions. However, background glial activation processes occurring throughout the brain are often overlooked and may contribute to long-term damage and cognitive decline in patients with TBI. Currently, there is increasing evidence to support the influence of endogenous lipid messengers such as N-acylethanolamines fatty acids in neuropathologies. Synaptamide (N-docosahexaenoylethanolamine) plays an important role in brain repair after neurotrauma due to its significant anti-inflammatory, gliotropic and neuroprotective effects. The aim of this study was to investigate the processes of reactive astrogliosis occurring in two brain regions (cortex and thalamus) following cerebral cortex injury and synaptamide therapy (10 mg/kg/day, 7 days) in mice. Synaptamide was shown to reduce the expression of brain damage biomarkers in the blood, inhibit the development of reactive astrogliosis, and trigger the activation of anti-inflammatory A2 type reactive astrocytes, with the synthesis of the main brain neurotrophins (Clcf1, BDNF) in vitro and in vivo. The therapeutic efficacy of synaptamide demonstrated in this study makes it a promising drug for the treatment of TBI. |
| format | Artículo científico |
| id | pubmed_40617897 |
| institution | PubMed |
| language | en |
| publishDate | 2025 |
| publisher | Inflammopharmacology |
| record_format | pubmed |
| spellingShingle | Synaptamide regulates astroglial functional activity after cerebral cortex injury. Manzhulo, Igor Egoraeva, Anastasia Ivashkevich, Darya Manzhulo, Olga Ponomarenko, Arina Animals Astrocytes Mice Cerebral Cortex Male Brain Injuries, Traumatic Ethanolamines Gliosis Neuroprotective Agents Mice, Inbred C57BL Brain-Derived Neurotrophic Factor Synaptamide regulates astroglial functional activity after cerebral cortex injury. Manzhulo, Igor Egoraeva, Anastasia Ivashkevich, Darya Manzhulo, Olga Ponomarenko, Arina Animals Astrocytes Mice Cerebral Cortex Male Brain Injuries, Traumatic Ethanolamines Gliosis Neuroprotective Agents Mice, Inbred C57BL Brain-Derived Neurotrophic Factor Modern approaches to the treatment of traumatic brain injury (TBI) focus on alleviating life-threatening conditions. However, background glial activation processes occurring throughout the brain are often overlooked and may contribute to long-term damage and cognitive decline in patients with TBI. Currently, there is increasing evidence to support the influence of endogenous lipid messengers such as N-acylethanolamines fatty acids in neuropathologies. Synaptamide (N-docosahexaenoylethanolamine) plays an important role in brain repair after neurotrauma due to its significant anti-inflammatory, gliotropic and neuroprotective effects. The aim of this study was to investigate the processes of reactive astrogliosis occurring in two brain regions (cortex and thalamus) following cerebral cortex injury and synaptamide therapy (10 mg/kg/day, 7 days) in mice. Synaptamide was shown to reduce the expression of brain damage biomarkers in the blood, inhibit the development of reactive astrogliosis, and trigger the activation of anti-inflammatory A2 type reactive astrocytes, with the synthesis of the main brain neurotrophins (Clcf1, BDNF) in vitro and in vivo. The therapeutic efficacy of synaptamide demonstrated in this study makes it a promising drug for the treatment of TBI. |
| title | Synaptamide regulates astroglial functional activity after cerebral cortex injury. |
| topic | Animals Astrocytes Mice Cerebral Cortex Male Brain Injuries, Traumatic Ethanolamines Gliosis Neuroprotective Agents Mice, Inbred C57BL Brain-Derived Neurotrophic Factor |
| url | https://pubmed.ncbi.nlm.nih.gov/40617897/ |